HOME >> MEDICINE >> NEWS
U of T study shows barriers to HIV vaccine acceptance

Public health officials must be sensitive to concerns about stigma and fear of vaccine-induced infection if they want women to take advantage of HIV vaccines now under development, says a University of Toronto researcher.

"The first generation of HIV vaccines may be available within 10 years but availability doesn't guarantee uptake," says U of T social work professor Peter A. Newman, one of the authors of a study in the June AIDS Education and Prevention. "Health-care officials must begin preparing now to address the social, behavioural and biological barriers they are likely to encounter in disseminating a future vaccine."

Through a series of focus groups with both health-care providers and women from at-risk populations in Los Angeles, Newman and colleagues from the University of California at Los Angeles and the Los Angeles County Health Department identified barriers to future HIV vaccine acceptance. In addition to worries about being labelled gay or promiscuous if they are vaccinated and fear of contracting HIV/AIDS from the vaccine, women in the focus groups were also concerned about power dynamics (the influence of husbands who are in denial about their own risk behaviours), affordability, reproductive side effects and discrimination in obtaining the vaccine.

However, the women also identified some strong motivations for getting vaccinated. Many viewed it as empowering to be able to protect themselves against HIV infection and others were eager to ensure their children were also protected. Both women and providers suggested that the vaccine be delivered as part of routine care so women would be able to take advantage of its protection without having to confront their partners and wouldn't have the stigma of obtaining care from HIV-identified services.

"These are all important factors to consider when a future vaccine is rolled out," says Newman. "Vaccines must be easy to obtain and affordable and women's particular concern
'"/>

Contact: Elaine Smith
elaine.smith@utoronto.ca
416-978-5948
University of Toronto
18-Jul-2005


Page: 1 2

Related medicine news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New study counts the economic cost of persistent pain in Australia
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Most seniors now have drug coverage, U-M study shows
7. To gain muscle and lose fat, drink milk: study
8. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
9. Even older women at high risk have little interest in being tested for HIV, study finds
10. Metabolic study in mice could lead to good cholesterol boosters
11. Michigan-CDC study supports value of social restrictions during influenza pandemics

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: study shows barriers HIV vaccine acceptance

(Date:5/23/2013)... United States Vice President Dick Cheney served as the ... , In front of 1,500 guests yesterday at ... "I am delighted to be here to have the ... Year Award. I think it's a tremendous recognition; I ... company like this because there are obviously a great ...
(Date:5/23/2013)... 23, 2013 Jeanne Ettelson, president of ... its popular and only free OCD support group in ... resource for OCD sufferers, the group is lead by ... disorders. This allows group participants to learn accurate ... Response Prevention. , “Participants in Beyond OCD’s support ...
(Date:5/23/2013)... News) -- The sensation of itching is hardwired into ... a small molecule released in the spinal cord, according ... say this molecule, known as natriuretic polypeptide b (Nppb), ... system. Ultimately, this signal is experienced as an itch. ... similar, the researchers concluded that a similar process probably ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Although a study ... the thinking and memory problems associated with Alzheimer,s ... have been unable to duplicate those findings. ... implications for patient safety since the drug involved ... effects, such as major blood-lipid abnormalities, pancreatitis, headaches, ...
(Date:5/23/2013)... Netsmart today announced it is ranked #49 ... technology (HIT) providers for 2013. , The HCI 100 listing ... Informatics magazine. Netsmart’s ranking of #49 is up from ... is largely due to our commitment to helping organizations forge ... resources are scarce, the demand for care is unprecedented and ...
Breaking Medicine News(10 mins):Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...
(Date:5/23/2013)... May 23, 2013 InspireMD, ... the leader in embolic protection stents, today announced ... Acute ST Elevation Reperfusion) trial demonstrating that the ... and drug eluting stents in all-cause mortality in ... from the trial were presented at the InspireMD ...
(Date:5/23/2013)... 2013  PAREXEL International Corporation (NASDAQ: PRXL ... the Jefferies Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... June 3, 2013. A live webcast of ... of PAREXEL,s website at www.PAREXEL.com in the ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5PAREXEL International To Present At Jefferies Healthcare Conference 2
Cached News: